Nxera Pharma Co., Ltd.
Nxera Pharma Co., Ltd. has 1 licensing announcement in this dataset, dated 2021-11-22.
- Country / operating region
- Japan
- Ticker
- 4565.T
- Headquarters
- 查無
- Founded
- 1990
- Business
- Biopharmaceutical research and development
- Website
- www.nxera.life
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Selective muscarinic receptor agonist portfolio | 查無 | 查無 | 查無 | 2021-11-22 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| Selective muscarinic receptor agonist portfolio | 查無 | — | 查無 | 查無 | 2022-02-10 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2021-11-22 | Neurocrine Biosciences, Inc. | Selective muscarinic receptor agonist portfolio | USD 100m | 查無 | ≤ USD 2600m | 查無 | Development / regulatory ≤ USD 1500m Sales ≤ USD 1100m |
| Counterparty | Territory | Royalties |
|---|---|---|
| Neurocrine Biosciences, Inc. | Worldwide for M4 and dual M4/M1; M1 excluding Japan, with co-development / profit-share options | Tiered up to mid-teen percentage royalties on net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無